Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
104.8900
1.6707
1.1940
.3361
.7393
8.4487
Low
81.0478
3.4810
Yes
No
No
No
Yes
Yes
0.9
No
No
No
No
Topotecan (CAS No.: 123948-87-8) is a widely researched and clinically used topoisomerase I inhibitor with significant antitumor activity. As a semi-synthetic derivative, topotecan mainly induces tumor cell cycle blockade and apoptosis by interfering with topological regulation during DNA replication and transcription, thereby exerting anticancer effects. It has shown good efficacy in treating various solid tumors such as ovarian cancer and small cell lung cancer, making it one of the important chemotherapy drugs in clinical practice. This paper provides a systematic review of the chemical structure, pharmacological activity, mechanism of action, druggability parameters, and clinical application prospects of topotecan, aiming to provide comprehensive and in-depth reference for researchers in the field of natural product pharmacology.
The molecular formula of topotecan is C23H23N3O5, with a molecular weight of 421.4530. Its structure is based on the typical framework of topoisomerase I inhibitors, containing a naphthalene structure with aromatic and nitrogen heterocycles, supplemented by multiple hydroxyl and carboxyl functional groups, giving it good water solubility and bioactivity. Its LogP value is 1.6707, indicating moderate lipid solubility, which facilitates membrane penetration. Topotecan has a polar surface area (TPSA) of 104.89 Ų, indicating that it has certain polar characteristics that facilitate binding to target proteins and distribution in vivo. Water solubility is 0.3361, which is not extremely high but sufficient to support its bioavailability for oral administration. Its lower blood-brain barrier penetration reduces the risk of central nervous system toxicity. The hERG channel suppression test result was negative, indicating a low risk of cardiotoxicity. The Ames test result was 0.9, indicating low mutagenicity and good safety.
Topotecan originally originated from the structural optimization and semi-synthetic modification of natural products such as paclitaxel compounds. Although it is a semi-synthetic drug itself, its parent structure is closely related to various natural products. The natural lead compounds of topoisomerase I inhibitors mainly come from plants such as Camptotheca acuminata, whose active ingredient Camptothecin forms the structural basis of topotecan. Camptothecin is obtained through complex extraction and purification processes, typically using organic solvents such as methanol or ethanol for extraction and separation and purification combined with column chromatography technology. Topotecan optimizes its water solubility and pharmacodynamic properties by chemically modifying the molecular structure of camptothecin. Currently, the production of topotecan mainly relies on chemical synthesis processes, combined with the structural advantages of natural products, achieving efficient and large-scale manufacturing.
Topotecan as a topoisomerase I inhibitor exhibits broad-spectrum antitumor activity. It mainly stabilizes the complex between topoisomerase I and DNA, blocking the reconnection process of DNA strands, leading to single-strand breakage and accumulation of DNA, which in turn triggers DNA damage reactions and induces tumor cell apoptosis. In vitro studies have shown that topotecan can induce cell cycle arrest in various tumor cell lines during G0/G1 and S phases, inhibiting cell proliferation. Its anti-cancer spectrum covers various solid tumors including ovarian cancer, small cell lung cancer, cervical cancer, and colorectal cancer.
In ovarian cancer models, topotecan exerts anti-tumor effects by regulating key molecules of various signaling pathways, such as BCL2, STAT3, ABCB1, TOP1, ESR1, NOS2, PIK3CA, MMP9, EGFR, and TP53. In particular, its effect on the multidrug resistance-related protein ABCB1 helps overcome tumor cell resistance. Additionally, topotecan can activate apoptotic signaling pathways within tumor cells, promote programmed cell death, and enhance the effectiveness of chemotherapy.
The core mechanism of action of topotecan is to block the superspiral relaxation process of DNA by inhibiting topoisomerase I (TOP1) activity. Topoisomerase I is an essential enzyme in cell replication and transcription, responsible for cleaving and relinking single-stranded DNA to maintain the stability of DNA topology. Topotechan forms a stable ternary complex with TOP1, preventing DNA strand reconnect, leading to single-strand breaks and accumulation, ultimately leading to cell death.
Additionally, topotecan affects several signaling molecules related to tumor development and development:
In summary, topotecan achieves effective inhibition of tumor cells through multi-target and multi-pathway synergistic effects.
The druggability parameters of topotecan indicate that it has promising potential for drug development. Moderate molecular weight and LogP values facilitate oral drug absorption and cell membrane penetration. A higher TPSA ensures affinity for the target protein. Although water solubility is limited, its bioavailability can be improved through formulation technology. The blood-brain barrier penetration ability is low, reducing the risk of adverse reactions in the central nervous system. hERG channel inhibition is negative, indicating a low risk of cardiotoxicity and good safety. Ames test results showed that it has low mutagenicity and meets drug safety requirements.
Pharmacokinetic studies show that topotecan is rapidly absorbed orally, with a short plasma peak concentration duration and moderate half-life, making it suitable for clinical administration regimens. Its main metabolic pathway is liver metabolism and excretion via the kidneys. Due to its regulatory effect on the multidrug resistant protein ABCB1, topotecan has potential advantages in treating drug-resistant tumors. Additionally, the pharmacokinetic characteristics of topotecan support its combination with other chemotherapy drugs to enhance therapeutic outcomes.
Topotecan, as a topoisomerase I inhibitor, has been approved for the treatment of recurrent ovarian cancer and small cell lung cancer, demonstrating good clinical efficacy and controllable safety. In the future, topotecan has broad application prospects in the field of precision cancer therapy. Through molecular targeting and genomics techniques, patients sensitive to topotecan can be screened out to achieve personalized treatment.
In addition, the combined use of topotecan with immune checkpoint inhibitors and targeted drugs may enhance anti-tumor effects and overcome resistance issues associated with monotherapy. The development of nanoformulations and sustained-release systems will also improve their pharmacokinetic properties, enhance efficacy, and reduce toxic side effects.
Future research should focus on in-depth analysis of topotecan's mechanism of action, strategies to overcome resistance mechanisms, and the development of novel delivery systems to promote its clinical application in more tumor types.
Topotecan, as a topoisomerase I inhibitor optimized based on natural product structure, has become an important player in the field of anticancer drugs due to its unique mechanism of action and broad-spectrum antitumor activity. Its excellent druggability parameters and safety provide a solid foundation for clinical application. With the advancement of molecular biology and medicinal chemistry, research on topotecan will further deepen, promoting its application in precision cancer therapy. In the future, through multidisciplinary collaboration, topotecan and its derivatives are expected to bring more benefits to cancer patients.
